Tsvia Fay-Karmon
Overview
Explore the profile of Tsvia Fay-Karmon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noy L, Hassin-Baer S, Fay-Karmon T, Kattouf N, Israeli-Korn S, van der Wel R, et al.
J Neuroeng Rehabil
. 2025 Mar;
22(1):51.
PMID: 40050876
Background: In general, people are unable to produce slow, smooth movements - as movements become slower (i.e., with longer durations), they become jerkier. A hallmark feature of Parkinson's disease is...
2.
Baker Erdman H, Bergman H, Haya K, Glowinsky S, Warhaftig L, Leon J, et al.
Eur J Neurosci
. 2025 Mar;
61(5):e70039.
PMID: 40045163
Nitrous oxide is a common gaseous anesthetic used in a wide range of medical procedures due to its desirable combination of anesthetic and analgesic properties. Deep brain stimulation surgery, a...
3.
Tamir-Ostrover H, Hassin-Baer S, Fay-Karmon T, Friedman J
Sensors (Basel)
. 2024 Jun;
24(11).
PMID: 38894110
People with Parkinson's disease often show deficits in dexterity, which, in turn, can lead to limitations in performing activities of daily life. Previous studies have suggested that training in playing...
4.
Anis S, Goldberg T, Shvueli E, Kozlov Y, Redlich Y, Lavi N, et al.
Parkinsonism Relat Disord
. 2024 Jan;
124:106008.
PMID: 38242744
Background: Deep brain stimulation (DBS) is a well-established treatment option for individuals with advanced Parkinson's disease (PD). The potential influence of the LRRK2 p.G2019S or GBA1 variants on its lasting...
5.
Anis S, Fay-Karmon T, Lassman S, Shbat F, Lesman-Segev O, Mor N, et al.
Neurogenetics
. 2023 Sep;
24(4):303-310.
PMID: 37658208
Alexander disease (AxD) is a rare autosomal dominant leukodystrophy caused by heterozygous mutations in the glial fibrillary acid protein (GFAP) gene. The age of symptoms onset ranges from infancy to...
6.
Goldberg T, Redlich Y, Yogev D, Fay-Karmon T, Hassin-Baer S, Anis S
Parkinsonism Relat Disord
. 2023 May;
112:105406.
PMID: 37211456
Background: Whole-plant medical cannabis (MC) products are widely used for controlling symptoms associated with Parkinson's disease (PD). Despite its widespread use, few studies have investigated the long-term impact of MC...
7.
Yahalom G, Fay-Karmon T, Livneh V, Israeli-Korn S, Ephraty L, Hassin-Baer S
Neurotox Res
. 2021 May;
39(4):1352-1359.
PMID: 34050898
Botulinum toxin (BT) injections into the cervical muscles are an effective and commonly practiced treatment approach for cervical dystonia. In this retrospective longitudinal study, we collected data from the Sheba...
8.
Yahalom H, Israeli-Korn S, Linder M, Yekutieli Z, Karlinsky K, Rubel Y, et al.
Clin Neuropharmacol
. 2019 Dec;
43(1):1-6.
PMID: 31815747
Objectives: We aimed to characterize parkinsonian features and gait performance of psychiatric patients on neuroleptics (PPN) and to compare them to Parkinson's disease (PD) and healthy controls (HC). Methods: Hospitalized...
9.
Yahalom G, Greenbaum L, Israeli-Korn S, Fay-Karmon T, Livneh V, Ruskey J, et al.
Parkinsonism Relat Disord
. 2018 Dec;
62:179-184.
PMID: 30573413
Introduction: The clinical characteristics of Parkinson's disease (PD) associated with both the LRRK2 p.G2019S mutation and a GBA variant (LRRK2-GBA-PD) have not yet been determined. Methods: In this retrospective observational...
10.
Ruskey J, Greenbaum L, Ronciere L, Alam A, Spiegelman D, Liong C, et al.
Eur J Med Genet
. 2018 May;
62(1):65-69.
PMID: 29842932
Background: Variants in GBA are the most common genetic risk factor for Parkinson's disease (PD), and are especially prevalent in the Ashkenazi Jewish (AJ) population. However, most studies on GBA...